DSOL (Drug Free Solution) Debt-to-EBITDA : 0.00 (As of Feb. 2014)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Drug Free Solution Debt-to-EBITDA?

Drug Free Solution DSOL +100.00% Debt-to-EBITDA is 0.00 as of Feb. 2014.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Drug Free Solution's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2014 was $0.00 Mil. Drug Free Solution's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2014 was $0.00 Mil. Drug Free Solution's annualized EBITDA for the quarter that ended in Feb. 2014 was $-0.47 Mil. Drug Free Solution's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2014 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Drug Free Solution's Debt-to-EBITDA or its related term are showing as below:

DSOL's Debt-to-EBITDA is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.25
* Ranked among companies with meaningful Debt-to-EBITDA only.

Drug Free Solution  (OTCPK:DSOL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Drug Free Solution Debt-to-EBITDA Related Terms

Drug Free Solution Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Drug Free Solution's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Drug Free Solution Debt-to-EBITDA Chart

Drug Free Solution Annual Data
Trend May12 May13
Debt-to-EBITDA
0.00 0.00

Drug Free Solution Quarterly Data
Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DSOL vs USEL, ZZLL, WSCO: Debt-to-EBITDA Comparison

For the Health Information Services subindustry, Drug Free Solution's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Drug Free Solution Debt-to-EBITDA vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Drug Free Solution's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Drug Free Solution's Debt-to-EBITDA falls into.


Drug Free Solution Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Drug Free Solution's Debt-to-EBITDA for the fiscal year that ended in May. 2013 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.755
=0.00

Drug Free Solution's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2014 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.468
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Feb. 2014) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of 0.00 mean?
Drug Free Solution (DSOL) has a Debt-to-EBITDA of 0.00 as of Feb. 2014. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Drug Free Solution.
Is Drug Free Solution's Debt-to-EBITDA too high?
Drug Free Solution's current Debt-to-EBITDA is 0.00.
How does Drug Free Solution's Debt-to-EBITDA compare to USEL and ZZLL?
Drug Free Solution's Debt-to-EBITDA of 0.00 can be compared against companies in the Healthcare Providers & Services industry. The industry median Debt-to-EBITDA is 2.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.25, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Drug Free Solution. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Drug Free Solution's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drug Free Solution stock overvalued right now?
Drug Free Solution (DSOL) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Drug Free Solution (DSOL), the current Debt-to-EBITDA is 0.00 as of Feb. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Drug Free Solution Business Description

Address 2211 Michelson Drive, Irvine, CA, USA, 92612
Drug Free Solution Inc is a United States based holding company that owns and operates various subsidiaries in the healthcare industry. It is focused on acquiring healthcare operations that focus on Home Healthcare, Developmental Disabilities, Hospice Care, Skilled Nursing, Residential Rehabilitation, Home & Community Based Services.